drugset

drugset / Trial / NCT05018221

Better Evidence and Translation for Calciphylaxis

NCT05018221 ↗

Phase 3 Recruiting 350 enrolled University of Sydney Australasian Kidney Trials Network · collab Berry Consultants · collab Northern Care Alliance NHS Foundation Trust · collab Vantive Health LLC · collab Waitemata District Health Board · collab

RandomizedSequentialQuadruple-blindTreatment

Summary

This global platform study will evaluate multiple interventions, across several domains of therapeutic care, in adult patients with kidney failure and newly diagnosed calciphylaxis.

Timeline

Start: 2021-08-26
Primary completion: 2029-12
Completion: 2029-12

Publications

Krishnasamy R, Jardine MJ; BEAT-Calci Trialists. Adaptive Designs for Clinical Trials in Nephrology. J Am Soc Nephrol. 2025 Jan 1;36(1):147-149. doi: 10.1681/ASN.0000000000000497. Epub 2024 Aug 26. No abstract available.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Magnesium Citrate	Unknown	150 mg	—
Subject	Sodium Thiosulfate	Diagnostic / imaging agent	25 g	Intravenous
Subject	Vitamin K	Unknown	10 mg	—

Indications